Overview
The investigators propose is to perform a pragmatic, multicenter, open-label, randomised clinical trial to demonstrate the efficacy and safety of either continuing or further de-escalating BMA after a minimum of two years of BMA treatment in patients with bone metastases from breast cancer and castration-resistant prostate cancer
Eligibility
Inclusion Criteria:
- Patients with either radiologically and/or histologically confirmed bone metastases from castrate resistant prostate cancer or breast cancer who are currently receiving BMA
- Patient has received BMA for 2 or more years counting from the first BMA dose for bone metastases
- Age 18 years or older
- Able to provide verbal consent
Exclusion Criteria:
- Definite contraindication for BMA
- History of, or current evidence of osteonecrosis of the jaw
- Radiotherapy or surgery to the bone planned within 4 weeks after randomization
- Current hypercalcemia defined as corrected serum calcium of > 3 mmol/L (from standard bloodwork completed within one month prior to treatment dose)